(Press-News.org) ROCHESTER, Minn. — Mayo Clinic researchers have developed a new artificial intelligence (AI) tool that helps clinicians identify brain activity patterns linked to nine types of dementia, including Alzheimer's disease, using a single, widely available scan — a transformative advance in early, accurate diagnosis.
The tool, StateViewer, helped researchers identify the dementia type in 88% of cases, according to research published online on June 27, 2025, in Neurology, the medical journal of the American Academy of Neurology. It also enabled clinicians to interpret brain scans nearly twice as fast and with up to three times greater accuracy than standard workflows. Researchers trained and tested the AI on more than 3,600 scans, including images from patients with dementia and people without cognitive impairment.
This innovation addresses a core challenge in dementia care: identifying the disease early and precisely, even when multiple conditions are present. As new treatments emerge, timely diagnosis helps match patients with the most appropriate care when it can have the greatest impact. The tool could bring advanced diagnostic support to clinics that lack neurology expertise.
The rising toll of dementia
Dementia affects more than 55 million people worldwide, with nearly 10 million new cases each year. Alzheimer's disease, the most common form, is now the fifth-leading cause of death globally. Diagnosing dementia typically requires cognitive tests, blood draws, imaging, clinical interviews and specialist referrals. Even with extensive testing, distinguishing conditions such as Alzheimer's, Lewy body dementia and frontotemporal dementia remains challenging, including for highly experienced specialists.
StateViewer was developed under the direction of David Jones, M.D., a Mayo Clinic neurologist and director of the Mayo Clinic Neurology Artificial Intelligence Program.
"Every patient who walks into my clinic carries a unique story shaped by the brain's complexity," Dr. Jones says. "That complexity drew me to neurology and continues to drive my commitment to clearer answers. StateViewer reflects that commitment — a step toward earlier understanding, more precise treatment and, one day, changing the course of these diseases."
To bring that vision to life, Dr. Jones worked alongside Leland Barnard, Ph.D., a data scientist who leads the AI engineering behind StateViewer.
"As we were designing StateViewer, we never lost sight of the fact that behind every data point and brain scan was a person facing a difficult diagnosis and urgent questions," Dr. Barnard says. "Seeing how this tool could assist physicians with real-time, precise insights and guidance highlights the potential of machine learning for clinical medicine."
Turning brain patterns into clinical insight
The tool analyzes a fluorodeoxyglucose positron emission tomography (FDG-PET) scan, which shows how the brain uses glucose for energy. It then compares the scan to a large database of scans from people with confirmed dementia diagnoses and identifies patterns that match specific types, or combinations, of dementia.
Alzheimer's typically affects memory and processing regions, Lewy body dementia involves areas tied to attention and movement, and frontotemporal dementia alters regions responsible for language and behavior. StateViewer displays these patterns through color-coded brain maps that highlight key areas of brain activity, giving all clinicians, even those without neurology training, a visual explanation of what the AI sees and how it supports the diagnosis.
Mayo Clinic researchers plan to expand the tool's use and will continue evaluating its performance in a variety of clinical settings.
For a complete list of authors, disclosures and funding, review the study.
###
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.
END
Mayo Clinic’s AI tool identifies 9 dementia types, including Alzheimer’s, with one scan
2025-06-27
ELSE PRESS RELEASES FROM THIS DATE:
Gene therapy improves blood flow in the brain in patients with sickle cell disease
2025-06-27
(MEMPHIS, Tenn. – June 27, 2025) Gene therapy for sickle cell disease may help improve a major contributing factor to stroke risk in patients, reports a new study from St. Jude Children’s Research Hospital. Many people with sickle cell disease experience increased brain ischemia, where oxygen is not delivered properly to brain tissues, potentially leading to strokes. A part of the risk for these events comes from increased blood flow speed in the brain. Findings from three patients in a gene therapy clinical trial showed ...
Building breast tissue in the lab to better understand lactation
2025-06-27
Human breast milk is uniquely adapted to meet an infant’s nutritional needs. Surprisingly, we still know very little about how milk is even made in the breast. A team of ETH Zurich researchers led by Marcy Zenobi-Wong, Professor of Tissue Engineering and Biofabrication, want to change that. In the lab, Zenobi-Wong and her team developed tiny replicas of lactating breast tissue. This involved isolating cells from human breast milk that are naturally found in milk. Some of the cells from lactating breast tissue and the so-called lactocytes – the cells in breast tissue that produce milk – end up in ...
How gut bacteria change after exposure to pesticides
2025-06-27
COLUMBUS, Ohio – While emerging evidence suggests pesticides can be toxic to the mix of microorganisms in the digestive system, a new study is the first to map changes to specific gut bacteria based on interactions between human microbes and insect-killing chemicals observed in the lab and an animal model.
The analysis showed that over a dozen pesticides influence human gut bacteria growth patterns, affect how gut microorganisms process nutrients and camp out inside some bacteria. Researchers say the resulting “atlas” ...
Timepoint at which developing B-cells become cancerous impacts leukemia treatment
2025-06-27
New findings show that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment outcomes for pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). Scientists at St. Jude Children’s Research Hospital and University Health Network’s Princess Margaret Cancer Centre, Toronto, developed a robust single-cell reference atlas of normal human B-cell development and cross-referenced single-cell B-ALL data with it, as well as outcomes data. The study, ...
Roberto Morandotti wins prestigious IEEE Photonics Society Quantum Electronics Award
2025-06-27
Roberto Morandotti Wins Prestigious IEEE Photonics Society Quantum Electronics Award
Congratulations to Professor Roberto Morandotti, the first researcher at INRS to receive this prestigious award in the field of quantum electronics
VARENNES, QC, June 27, 2025 – Professor Roberto Morandotti, a globally recognized leader in quantum optics and photonics at the Institut national de la recherche scientifique (INRS), has won the 2025 Institute of Electrical and Electronics Engineers (IEEE) Photonic Society Quantum Electronics Award. This award pays ...
New urine-based tumor DNA test may help personalize bladder cancer treatment
2025-06-27
In a multi-institutional study published in Science Direct, researchers revealed that testing urine-based tumor DNA (utDNA) can help predict which bladder cancer patients are at higher risk for recurrence after treatment.
This study analyzed utDNA from patients in the SWOG S1605 trial, who were treated with atezolizumab, an immunotherapy drug. Researchers used the UroAmp test to examine urine samples from 89 patients at the start of treatment and from 77 patients three months later. The goal was to see if utDNA could help identify which bladder cancer patients are most likely to respond to immunotherapy.
“This approach could help improve patient ...
How a faulty transport protein in the brain can trigger severe epilepsy
2025-06-27
Citrate is essential for the metabolism and development of neurons. A membrane transport protein called SLC13A5 plays a central role in this process and has previously been linked to a particularly severe form of epileptic encephalopathy. Building on data from the recently completed RESOLUTE and REsolution flagship projects, scientists at CeMM have comprehensively studied the function and structure of the membrane transporter SLC13A5, experimentally investigating 38 mutant variants. Their findings, published in Science Advances (DOI 10.1126/sciadv.adx3011) shed new light on the mechanisms of this disease and lay the ...
Study reveals uneven land sinking across New Orleans, raising flood-risk concerns
2025-06-27
Parts of New Orleans and its surrounding wetlands are gradually sinking, and while most of the city remains stable, a new study from Tulane University researchers suggests that sections of the region’s $15 billion post-Katrina flood protection system may need regular upgrades to outpace long-term land subsidence.
The study, published in Science Advances, used satellite radar data to track subtle shifts in ground elevation across Greater New Orleans between 2002 and 2020. The study found that some neighborhoods, wetlands and even sections of floodwalls are sinking by more than an inch per year — with some ...
Researchers uncover novel mechanism for regulating ribosome biogenesis during brain development
2025-06-27
Ribosomes are tiny molecular machines inside all living cells that build proteins, and ribosome biogenesis is the complex, multi-step process by which they are made.
During brain development, neural stem cell proliferation relies on active ribosome biogenesis to meet high protein demand. This process involves the concerted action of numerous ribosomal RNA processing factors and assembly proteins. Studies have shown that precise regulation of ribosome biogenesis is essential for normal brain development and tumor prevention.
N6-Methyladenosine ...
RNA codon expansion via programmable pseudouridine editing and decoding
2025-06-27
Peking University, June 27, 2025: To overcome the inherent challenge of translation termination interference caused by stop codon reprogramming in mammalian cells, researchers from Peking University led by Chen Peng from College of Chemistry and Molecular Engineering and Yi Chengqi from School of Life Sciences have developed a novel codon expansion strategy that enables precise incorporation of noncanonical amino acids (ncAAs) without perturbing natural genetic codes. This innovative approach utilizes post-transcriptionally modified RNA codons—distinct from all 64 standard genetic codons—within targeted transcripts to encode ncAAs ...